CA stem cell agency exploring options
The California Institute for Regenerative Medicine (CIRM) is exploring options for its future as funding provided through its bond issue dwindles. In a meeting earlier this week, two governing board committees of the agency focused on short and long term finances including a proposal to cut clinical awards by $68 million over the next two years, an effort to raise $222 million in private funding, and the possibility of a $5 billion ballot initiative in November 2020, according to the California Stem Cell Report. The original $3 billion bond issue passed in 2004 was expected to produce research breakthroughs which have not yet resulted in widespread use. The full board is meeting Dec. 14 and may consider the proposals then.